DOI: 10.1093/ejhf/xuag193.193 ISSN: 1388-9842

Differential effects of sodium-glucose cotransporter 2 inhibitors and sacubitril-valsartan in incidence of heart failure with improved ejection fraction

M Moreira, I Bastos Castro, J Luis Ferraro, I Gomes Campos, A Rodrigo Costa, J Ponte Monteiro, I Almeida, A Leal Neto, A Pereira, P Silva, A Andrade

Abstract

Introduction

Heart failure with improved ejection fraction (HFimpEF) is increasingly recognized as a meaningful phenotype. The impact of guideline directed medical therapy (GDMT) and its titration on HFimpEF incidence still needs to be clarified.

Methods

Single-center retrospective study with consecutive patients with chronic dilated cardiomyopathy and reduced ejection fraction from a heart failure clinic, between 2014-2024. Previous diseases, medication (including GDMT according to percentage of target dose), clinical status, biomarkers, electrocardiogram and echocardiogram findings were recorded. HFimpEF (left ventricle ejection fraction ≥40% with improvement of ≥10% from baseline) was the endpoint at 1-year post-admission.

Results

We included 189 patients (69.3% male; mean age 58.4±12.2 years-old), median LVEF of 26.8±10.7% at baseline. HFimpEF occurred in 37.1% of patients. Both at baseline and at 1-year, these patients were more likely to be on sodium-glucose cotransporter 2 inhibitors (SGLT2i) (66.1% vs 41.9%; p=0.002; 72.1% vs 51.4%; p=0.029, respectively) and on combined therapy with angiotensin-converting enzyme inhibitors (ACEi) or sacubitril-valsartan (ARNI), beta blocker (BB), SGLT2i and mineralocorticoid receptor antagonist (MRA), regardless of their doses (51.6% vs 34.4%; p=0.01; 62.3% vs 41.0%; p=0.008, respectively). Additionally, at 1-year, HFimpEF patients were also more often medicated with ARNI (60.7% vs 41.0%; p=0.014). A stronger association was evident for ARNI at target dose (37.7% vs 15.2%; p<0.001).

Conclusion

This study suggests that SGLT2i and ARNI, particularly when used at target dose, are the only HFrEF therapeutic pillars associated with HFimpEF in patients with dilated cardiomyopathy

More from our Archive